SCHEMBL20903501

SCHEMBL20903501

N#Cc1cccc(-c2cccc(-c3nc(-c4ccccc4)nc(-c4ccc(-c5cccc(C(=C(c6ccccc6)c6ccccc6)c6ccccc6)c5)cc4)n3)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 6/20 0.50
▸ CLK4 Q9HAZ1 5/20 0.50
▸ CYP3A4 P08684 5/20 0.50
▸ MEN1 O00255 4/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ KMT2A Q03164 4/20 0.50
▸ LMNA P02545 4/20 0.50
▸ CYP2D6 P10635 4/20 0.50
▸ CYP2C19 P33261 3/20 0.50
▸ HSD17B10 Q99714 3/20 0.50
▸ TSHR P16473 2/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ KAT6A Q92794 2/20 0.48
▸ MAPK1 P28482 2/20 0.47
▸ XDH P47989 1/20 0.47
▸ SLC22A12 Q96S37 1/20 0.47
▸ TP53 P04637 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ USP2 O75604 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20903516 0.93 KAT6A (0.49) CYP1A2CLK4CYP3A4MEN1ALDH1A1
SCHEMBL20903590 0.93 KAT6A (0.52) CYP1A2CLK4CYP3A4MEN1ALDH1A1
SCHEMBL20903478 0.92 CYP1A2 (0.47) CYP1A2CLK4CYP3A4MEN1ALDH1A1
SCHEMBL20903628 0.90 KAT6A (0.51) CYP1A2CLK4CYP3A4MEN1ALDH1A1
SCHEMBL23383758 0.90 CYP1A2 (0.58) CYP1A2CLK4CYP3A4MEN1ALDH1A1
SCHEMBL23384205 0.90 CYP1A2 (0.58) CYP1A2CLK4CYP3A4MEN1ALDH1A1
SCHEMBL23383906 0.90 CYP1A2 (0.58) CYP1A2CLK4CYP3A4MEN1ALDH1A1
SCHEMBL23384099 0.90 CYP1A2 (0.58) CYP1A2CLK4CYP3A4MEN1ALDH1A1
SCHEMBL23384197 0.90 CYP1A2 (0.58) CYP1A2CLK4CYP3A4MEN1ALDH1A1
SCHEMBL23384202 0.90 CYP1A2 (0.58) CYP1A2CLK4CYP3A4MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3470398-B1 ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER NOVALED GMBH (DE) 2022-05-04 — — EP disclosed
US-20200317704-A1 Organic Electronic Device Comprising an Organic Semiconductor Layer NOVALED GMBH (DE) 2020-10-08 — — US disclosed
WO-2019072932-A1 ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER NOVALED GMBH (DE) 2019-04-18 — — WO disclosed
EP-3470398-A1 ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTOR LAYER Novaled GmbH (DE) 2019-04-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317704-A1 Organic Electronic Device Comprising an Organic Semiconductor Layer SELE, EPCAM, OR51E2 CYP1A2 957/4885CLK4 1742/4885CYP3A4 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback